Enanta Pharmaceuticals, Inc.
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identifyā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.44
Price-3.24%
-$0.45
1Y
Price
Market Cap
$286.726m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-107.6%
EBITDA Margin-123.6%
Net Profit Margin+114.7%
Free Cash Flow Margin-107.6%
EBITDA Margin-123.6%
Net Profit Margin+114.7%
Free Cash Flow MarginRevenue
$65.324m
-3.4%
1y CAGR-8.7%
3y CAGR-9.3%
5y CAGREarnings
-$81.889m
+29.4%
1y CAGR+10.9%
3y CAGR-5.3%
5y CAGREPS
-$3.84
+30.1%
1y CAGR+12.1%
3y CAGR-3.6%
5y CAGRBook Value
$64.717m
$280.732m
Assets$216.015m
Liabilities$201.056m
DebtDebt to Assets
71.6%
-2.8x
Debt to EBITDAFree Cash Flow
-$32.168m
+55.0%
1y CAGR+13.2%
3y CAGR+4.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company